Amid Regulatory and Reimbursement Difficulties, Some Encouraging Advancements for Personalized Rx
This is the second article in a two-part feature on the state of personalized drug development. The first part, published last week, focused on the scientific challenges facing the industry. This latest piece is about the evolving regulatory and financial environment and recent advances in the field.
New to GenomeWeb? Register here quickly.